Rilpivirine in combination with cabotegravir is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents - ≥12 years old and weighing at least 35kg - to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
All Rilpivirine-related impurity standards are available from Venkatasai, together with certified COAs and characterization data like IR, mass, HPLC, purity, NMR, and TGA reports. In accordance with the regulations, we also offer CMR, DEPT, and thorough structure characterization reports. Major pharmaceutical companies all around the world employ standards connected to Rilpivirinef or their ANDA/DMF applications.